Title: Community and Household Acute Respiratory Illness Monitoring (CHARM) Study

Brief Title: CHARM Study

Brief Summary: The CHARM Study is an observational study to gather important data on respiratory viral illnesses in communities in the Greater Boston Area. We will study how often respiratory viral illnesses occur - like COVID19 and influenza - and how these viruses are spread. Our goal is to improve public health interventions to prevent disease.

Title: A Phase 2a Randomized, Dose Ranging, Double-Blind, 3-Arm Study to Investigate Orally Administered Abrocitinib Compared with Placebo in Non-Hospitalized Symptomatic Adult Participants with Severe Fatigue from Post COVID Condition

Brief Title: CLEAR-LC CLinical Eval Abrocitinib Recovery from Long COVID

Brief Summary: The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).

Title: A Data and Tissue Repository to Facilitate Infectious Diseases Research and Advance Pandemic Preparedness, with a Focus on Respiratory Pathogens

Brief Title: A Data and Tissue Repository for Respiratory Pathogens

Brief Summary: The purpose of this study is to collect samples and clinical information from people with symptoms of an acute respiratory illness, such as cough, fever and muscle pain. These are symptoms that are typical of influenza, COVID-19 and other viral infections. We are also collecting samples from people without any symptoms. The goal of the study is to store these samples to help researchers prepare for future outbreaks of infectious diseases.

Title: General Pre-Trial Screening Protocol for Enrollment of Volunteers into Infectious Diseases Research Protocols

Brief Title: General Pre-Trial Screening Protocol

Brief Summary: The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) at BIDMC. This protocol will help us to determine whether a volunteer is eligible for completing the screening process, and which protocols they may be good candidates for.

Title: HVTN 307: A phase 1 clinical trial to evaluate the safety and immunogenicity of ferritin nanoparticles expressing native-like HIV-1 envelope trimers followed by boost with mRNA lipid nanoparticles encoding a native-like HIV-1 envelope trimer in adults without HIV

Brief Title: HVTN 307

Brief Summary: This first-in-human (FIH) phase 1 clinical trial will evaluate a prime-boost regimen of immunogens designed to induce HIV-1 Env V3-glycan-specific broadly neutralizing antibodies (V3G bNAbs). The priming immunogen (V3G CH848 Pr-NP1) consists of ferritin NPs expressing 8 copies of an Env trimer. This immunogen will be boosted with an mRNA LNP (V3G CH848 mRNA-Tr2), encoding a soluble Env trimer which does not utilize the ferritin NP design.

Title: HVTN 142: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV

Brief Title: HVTN 142

Brief Summary: The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.

Title: SARS-CoV-2 Household Transmission Study

Brief Title: SARS-CoV-2 Household Transmission Study

Brief Summary: We are conducting this study to see how SARS-CoV-2 is transmitted from one person to another within a household, and to see if COVID-19 vaccination can help prevent SARS-CoV-2 transmission. We are enrolling people who have recently tested positive for COVID-19 (or were recently exposed or have symptoms of COVID-19), as well as people who live in a household with someone who potentially might have COVID-19. The study lasts up to 4 weeks. If you participate, we will ask you to swab your nose every day for 14 days so we can test for COVID19. We will also ask for a couple blood draws, but these are optional. You would receive up to $50 to compensate you for participation.